

Integrated Innate Mechanisms Involved in Airway Allergic Inflammation to the Serine Protease Subtilisin

Esther Florsheim,^{*,†} Shuang Yu,[†] Ivan Bragatto,[‡] Lucas Faustino,^{*} Eliane Gomes,^{*} Rodrigo N. Ramos,^{*} José Alexandre M. Barbuto,^{*} Ruslan Medzhitov,[†] and Momtchilo Russo^{*}

Proteases are recognized environmental allergens, but little is known about the mechanisms responsible for sensing enzyme activity and initiating the development of allergic inflammation. Because usage of the serine protease subtilisin in the detergent industry resulted in an outbreak of occupational asthma in workers, we sought to develop an experimental model of allergic lung inflammation to subtilisin and to determine the immunological mechanisms involved in type 2 responses. By using a mouse model of allergic airway disease, we have defined in this study that s.c. or intranasal sensitization followed by airway challenge to subtilisin induces prototypic allergic lung inflammation, characterized by airway eosinophilia, type 2 cytokine release, mucus production, high levels of serum IgE, and airway reactivity. These allergic responses were dependent on subtilisin protease activity, protease-activated receptor-2, IL-33R ST2, and MyD88 signaling. Also, subtilisin stimulated the expression of the proallergic cytokines IL-1 α , IL-33, thymic stromal lymphopoietin, and the growth factor amphiregulin in a human bronchial epithelial cell line. Notably, acute administration of subtilisin into the airways increased lung IL-5–producing type 2 innate lymphoid cells, which required protease-activated receptor-2 expression. Finally, subtilisin activity acted as a Th2 adjuvant to an unrelated airborne Ag-promoting allergic inflammation to inhaled OVA. Therefore, we established a murine model of occupational asthma to a serine protease and characterized the main molecular pathways involved in allergic sensitization to subtilisin that potentially contribute to initiate allergic airway disease. *The Journal of Immunology*, 2015, 194: 000–000.

The incidence and severity of allergic disease are on the rise, with 30–40% of the world population affected in 2011 (1). Asthma is considered a chronic inflammatory syndrome of the airways and represents one of the most studied lung diseases. Classically, asthma is triggered by the activation of a Th2 adaptive immune response that induces lung eosinophilia, mucus production, increased levels of IgE, and airway remodeling and hyperactivity (2). Despite the fact that allergic asthma is phenotypically well characterized, the mechanism behind allergen sensitization and initiation of the Th2 response is poorly understood.

Occupational asthma (OA) is a work-related lung disease induced by exposure to an occupational allergen. The prevalence of OA depends on the nature of the allergen workers are exposed to, the intensity and duration of this exposure, and individual sus-

ceptibility (3–5). Contact with proteases at the workplace is an important risk factor for the development of OA (4). Protease-induced OA was first recognized at the end of the 1960s and the 70s when heat-stable alkaline enzymes, such as Carlsberg subtilisin, were introduced to washing detergents. After inclusion of Carlsberg subtilisin, >50% of workers from the detergent industry developed allergic asthma, IgE production, and airway hyperactivity (6). This suggested that Carlsberg subtilisin (alcalase), a serine protease isolated from *Bacillus* species, acted as an allergen and could induce OA (7). However, despite the observed link between occupational exposure to subtilisin and asthma, the mechanisms through which subtilisin could trigger the allergic responses remained elusive. Therefore, the development of an experimental model for the investigation of subtilisin-induced allergic lung disease could provide useful insights into the general mechanisms behind allergic reactions to proteases.

Many allergens can initiate the allergic response, of which one important and understudied class is proteases. Protease activity has been implicated in the development of type 2 inflammation in response to allergens (8). Indeed, several studies suggest that proteases are an important component in the allergenic potential of urban substances (9–15). However, proteases do not always represent the major allergens. Even though, proteases could act as Th2 adjuvants to bystander Ags present in the same environment (8, 16, 17).

In this study, we characterized an experimental model of OA to subtilisin induced by s.c. or intranasal (i.n.) sensitization. We found that subtilisin serine protease activity was essential for allergic sensitization and subsequent airway inflammation. Furthermore, we found that the allergenicity of subtilisin depended upon protease-activated receptor (PAR)-2, IL-33R ST2, and MyD88. Moreover, exposure of a human bronchial epithelial cell line to subtilisin induced proallergic cytokines, such as thymic stromal

^{*}Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, 05508-000 SP Brazil; [†]Department of Immunobiology, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06510; and [‡]Department of Biochemistry, Institute of Chemistry, University of Sao Paulo, Sao Paulo, 05508-000 SP Brazil

ORCID: 0000-0002-5889-7442 (E.F.).

Received for publication October 8, 2014. Accepted for publication March 1, 2015.

This work was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Pesquisa, Brazil, the National Institutes of Health, and the Howard Hughes Medical Institute.

Address correspondence and reprint requests to Prof. Momtchilo Russo, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Avenida Professor Lineu Prestes, 1730 Sao Paulo, 05508-000 SP Brazil. E-mail address: momrusso@icb.usp.br

The online version of this article contains supplemental material.

Abbreviations used in this article: BAL, bronchoalveolar lavage; BM, bone marrow; DC, dendritic cell; ILC2, type 2 innate lymphoid cell; i.n., intranasal(ly); OA, occupational asthma; PAR, protease-activated receptor; Penh, enhanced pause; TSLP, thymic stromal lymphopoietin; WT, wild-type.

Copyright © 2015 by The American Association of Immunologists, Inc. 0022-1767/15/\$25.00

lymphopoietin (TSLP), IL-1 α , and IL-33, and the tissue repair factor, amphiregulin. Finally, inhaled subtilisin increased lung type 2 innate lymphoid cells (ILC2) and acted as a Th2 adjuvant to a bystander Ag such as inhaled OVA.

Materials and Methods

Mice

Female (8–12 wk old) C57BL/6 wild-type (WT), MyD88^{-/-}, PAR-2^{-/-}, and TLR4^{-/-} mice were from the Institute of Biomedical Sciences-IV, University of Sao Paulo, or Yale Animal Resources Center at Yale University, originally from The Jackson Laboratory. C57BL/6 Il1rl1^{-/-} mice were provided by A. McKenzie (University of Cambridge). Mice were bred in specific pathogen-free conditions, and experiments were done in accordance with approved guidelines determined by the ethical principles of Animal Care of the Institute of Biomedical Sciences at University of Sao Paulo or Institutional Animal Care and Use Committee at Yale.

Chimeric mice were generated following a standard protocol (18). C57BL/6 CD45.1 and PAR-2^{-/-} mice were used as donors and/or recipients in bone marrow (BM) transplant experiments. Recipient mice underwent a lethal total-body irradiation with 2 doses of 500 rad (Gammacell 40 ¹³⁷Cs γ -irradiation source), with an interval of 4 h between the first and second irradiations. Fresh, unseparated BM cells (10×10^6 per mouse) were injected into the tail vein of the irradiated recipient mice 24 h after lethal irradiation. Chimerism efficiency was checked by FACS 8 wk postirradiation and transplant using peripheral blood, and reconstituted mice were used at 2 mo after BM transplantation.

Reagents and Abs

Subtilisin (EC 3.4.21.62), papain (EC 3.4.22.2), grade V OVA, and PMSF were purchased from Sigma-Aldrich. E-64 and the fluorogenic substrates AAF-AMC and Z-R-AMC were from Calbiochem Merck Millipore. OVA was removed from LPS using Triton X-114, and the remaining endotoxin activity was measured by LAL QCL-1000 kit (BioWhittaker). The following reagents are from the indicated sources: ACK lysing buffer (Lonza), FCS (Benchmark), SMART Moloney murine leukemia virus reverse-transcriptase reagents (Clontech), and SYBR Green quantitative PCR mix (Quanta). Purified anti-mouse fluorochrome-conjugated Abs to CD16/CD32 (2.4G2), I-A^d and I-E^d, Siglec-F, CD4, CD8 α , CD45, IL-2, IL-4, IL-5, IL-13, IL-17A, IFN- γ , lineage markers (CD3e, CD19, CD11b, CD11c, NK1.1, Ly-6G, Fc ϵ RI), and Thy-1.2 (CD90.2) were all from BD Biosciences or eBioscience.

Enzymatic assays

Protease assays were routinely performed at 30°C with 10 mM substrates in saline with 1 mM Ca²⁺ (subtilisin) or PBS with 5 mM L-cysteine (papain), both pH 7.4. Protease activity was measured by fluorescence detection of methylcoumarin released over time in a microplate fluorimeter (Gemini XPS; Molecular Devices). Enzyme activities were proportional to protein concentration and time. For inhibition assays, subtilisin was heat inactivated after incubation for 5 min at 100°C. Protein and remaining protease activity were determined in the supernatant and precipitate after centrifugation for 10 min at $10,000 \times g$ and 4°C. Alternatively, subtilisin and papain were incubated with different concentrations of PMSF or E64, respectively, until no further inhibition was detected prior to enzyme assay. For in vivo studies, 10 μ M PMSF and 50 nM E-64 were used.

Induction of allergic airway inflammation

Mice were s.c. injected with 1 μ g subtilisin or 5 μ g papain with or without 1.6 mg alum or i.n. with 1 μ g active or heat-inactivated subtilisin plus 5 μ g OVA on days 0 and 7. To induce airway inflammation after sensitization, anesthetized mice were administered i.n. with 1 μ g subtilisin, 5 μ g papain, or 10 μ g OVA in 40 μ l final volume on days 14 and 21. On day 22, mice were euthanized and different parameters were analyzed. For the acute inflammation model, mice received 1 μ g i.n. subtilisin on days 0 and 7, and the experiment was performed on day 8. For lung ILC2 studies, mice received 1 μ g subtilisin for consecutive 3 d and experiments were performed on day 4. Alum gel was prepared, as previously described (19).

Analysis of inflammatory responses

BAL was collected after injecting 1 ml PBS. Total and differential cell counts were determined by hemocytometer and cytospin preparation and stained with Instant-Prov (Newprov). Lung tissue was digested using collagenase IV (2 mg/ml) and DNase I (1 mg/ml) (Sigma-Aldrich) at 37°C for 30 min. Single-cell suspension was obtained after erythrocyte depletion, smashing, and filtering. Total lung cells were restimulated ex vivo

with 100 ng/ml PMA and 750 ng/ml ionomycin (Sigma-Aldrich) for 4 h or 1 μ g/ml subtilisin for 18 h both in RPMI 1640 medium at 37°C.

Single-cell suspensions from BAL and lung were blocked with 2.4G2 and incubated for 25 min at 4°C with Abs. A Cytofix/Cytoperm Plus kit with GolgiPlug (BD Pharmingen) was used for intracellular cytokine staining, according to the manufacturer's instructions. Cell acquisition was performed on Canto II or LSRII instruments (BD Biosciences), and data were analyzed with FlowJo software (Tree Star).

Determination of respiratory pattern

Respiratory dynamics of mice were monitored using unrestrained whole-body plethysmography (Buxco Electronics, Troy, NY), and measurements were obtained at baseline and after stimulation with inhaled methacholine (0, 3, 6, 12, and 25 mg/ml) from Sigma-Aldrich, as previously described (20). Enhanced pause (Penh) is a dimensionless value that represents a function of the ratio of peak expiratory flow to peak inspiratory flow and a function of the timing of expiration. Penh correlates with pulmonary airflow resistance or obstruction. Penh as measured by plethysmography has been previously validated in animal models of airway hyperresponsiveness (21).

To determine airway reactivity, Penh was recorded for 7.5 min after each methacholine challenge and at baseline. For late-phase response analysis, Penh was measured each hour for 6 h right after the second subtilisin challenge, on day 21 of the experimental protocol described in *Materials and Methods*. In this case, Penh was determined without methacholine challenge.

Determination of Abs and cytokines

Total IgE was assayed by sandwich ELISA (OptEIA ELISA Set BD) following the manufacturer's instructions. For specific IgG1 quantification, OVA or subtilisin (both at 2 μ g/ml) was plated overnight at 4°C. Plates were blocked with 10% FBS; mouse serum was added at multiple dilutions; and specific IgG1 was detected with HRP anti-mouse IgG1 (Invitrogen). Purified mouse IgG1 (Invitrogen) was used as standard. For OVA-specific IgE, plates were coated with anti-IgE (Southern Biotech), and subsequently, biotin-labeled OVA was added. Bound OVA-biotin was revealed and OVA-specific IgE levels of samples were deduced from an internal standard arbitrarily assigned as 1000 U, as previously established (22).

BAL specimens were assessed for concentrations of IL-4, IL-6, IL-10, and TNF- α at day 22 after s.c. sensitization and i.n. challenge with subtilisin by cytometric bead array using the BD CBA Mouse Th1/Th2/Th17 Cytokine Kit (BD Biosciences), according to the manufacturer's instructions. Samples were quantified using Canto II (BD Biosciences) flow cytometer and analyzed by FCA array software (BD Biosciences).

Lung histology

Lungs were perfused through the right ventricle with 5 ml PBS, removed, and immersed in 10% phosphate-buffered formalin for 24 h, followed by 70% ethanol until embedding in paraffin. Tissues were sliced, and 5- μ m sections were stained with H&E or periodic acid-Schiff for analysis of cellular inflammation and mucus production, respectively.

Analysis of human epithelial cell activation

Human airway epithelial cells (H292; American Type Culture Collection) were cultured as indicated by the manufacturer. Confluent cultures were serum starved for 12 h before the addition of active subtilisin (1.0 or 10 μ g/ml) or papain (10 μ g/ml). Cell lysates were harvested after stimulation for 3 or 6 h. Total RNA was isolated using RNA-Bee reagent and was reverse transcribed with an oligo(dT) primer and a Moloney murine leukemia virus reverse transcriptase reagent. cDNA was synthesized by SuperScriptIII (Roche) and random primers and analyzed in triplicate by quantitative PCR amplification using SYBR Green Supermix on a Bio-Rad CFX96 Real-Time PCR Detection System. Relative expression was normalized to ribosomal protein L22 (*Rpl22a*). Data are represented as the relative fold induction over unstimulated cells and are representative of three independent experiments, each of them with triplicate samples.

Study subjects

Three healthy nonatopic and nonsmoking female individuals, 23–34 y old, with no family history of asthma and allergy, were chosen to participate in the study. All volunteers gave written, informed consent. The protocol was approved by the Institutional Ethics Committee (2009/902 CEP).

Dendritic cell differentiation and allergen pulse

PBMCs were isolated from blood collected in heparin (50 U/ml) by centrifugation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Uppsala,

Sweden), as previously described (23). Briefly, mononuclear cells were resuspended and seeded in RPMI 1640 culture medium (Life Technologies, Grand Island, NY), supplemented with 10% FCS (Life Technologies) plus antibiotic-antimycotic (100 U/ml penicillin, 100 µg/ml streptomycin, and 25 µg/ml amphotericin; Life Technologies). Culture plates were incubated at 37°C overnight, and nonadherent cells were cultured with GM-CSF (50 ng/ml; R&D Systems, Minneapolis, MN) and IL-4 (50 ng/ml; R&D Systems). Monocyte-derived immature dendritic cells (DCs) were harvested at day 7 and stimulated overnight with 1 µg/ml active or heat-inactivated subtilisin. Cells stimulated with 500 ng/ml LPS (*Escherichia coli* 0111:B4; Sigma-Aldrich) were taken as positive control, whereas unstimulated cells (in serum-free medium) were used as negative control. On day 8, nonadherent mature DCs were harvested, and 2.5×10^5 cells/condition were labeled with specific fluorescent Abs (CD11c, CD14, CD80, CD83, CD86, HLA-DR, or isotype controls; all from BD Biosciences or eBioscience) and acquired on Canto II flow cytometer. Samples were analyzed using the FlowJo software (Tree Star).

T cell stimulation assay

Eight days after initiation of monocyte DCs culture, heterologous nonadherent lymphocytes were obtained from healthy volunteers. Monocyte-matured DCs pulsed with active, heat-inactivated subtilisin or LPS were cocultured in 96-well U-bottom culture plates with heterologous lymphocytes, in triplicates at a ratio of 1:10 in RPMI 1640 medium supplemented with 10% FCS plus antibiotic-antimycotic solution. After 5 d of coculture, CD3⁺ T cells were phenotypically evaluated as to their cytokine production after intracellular staining for IL-4, IL-10, TNF-α, and IFN-γ (all Abs and isotype controls are from BD Biosciences or eBioscience).

Statistical analysis

Statistical analyses were performed with *t* tests (Mann–Whitney for unpaired data) or ANOVA, as appropriate. Differences were considered significant when *p* < 0.05.

Results

Experimental model of OA induced by subtilisin

To establish a model of subtilisin-induced OA, mice were sensitized with two s.c. sensitizations followed by two i.n. challenges, as depicted in Fig. 1A, and as previously described (24). Sensitization and challenge with subtilisin induced high levels of serum IgE, and this production was enhanced when mice were sensitized to subtilisin in the absence of alum (Fig. 1B). The specific IgG1 response induced by subtilisin was also increased in sensitized and challenged animals, and it was similar in magnitude comparing sensitization with or without alum (Fig. 1C). We found that administration of subtilisin without adjuvant during sensitization induced an intense airway eosinophilic inflammation, as revealed by total (Fig. 1D) and differential cell counts (Fig. 1E) in BAL. Similar results were obtained using papain, a cysteine protease known to induce occupational allergy (25) (Fig. 1B, 1D, 1E). Lung histology showed pronounced airway inflammation and mucus formation in mice sensitized to subtilisin alone compared with subtilisin/alum or control groups (Fig. 1F). Moreover, subtilisin challenge promoted increased bronchoconstriction to inhaled methacholine, a hallmark of asthma (Supplemental Fig. 1A). Interestingly, subtilisin was also able to induce the late-phase response in sensitized mice, characterized by altered respiratory pattern after specific allergen challenge (26) (Supplemental Fig. 1B). Together, these data demonstrate that subtilisin by itself is a potent inducer of allergic lung disease.

Because mice sensitized with protease plus alum, a pro-Th2 adjuvant, showed decreased Th2 responses compared with mice sensitized with protease alone, alum could interfere with subtilisin allergenicity. We found that alum reduced protease activity in a dose-dependent manner (Fig. 1G), suggesting that protease activity might play a role in the allergenicity of subtilisin.

Protease activity of subtilisin initiates the development of allergic inflammation through PAR-2

We next sought to determine whether the allergenicity of subtilisin depended upon its protease activity. Incubation of subtilisin or papain with specific inhibitors, PMSF or E-64, respectively, virtually eliminated protease activity (93–97% of inhibition; data not shown). Sensitization of mice with pharmacologically inactivated subtilisin reduced recruitment of inflammatory cells to the airways after challenge with active protease (Fig. 2A, 2B). Analysis by flow cytometry confirmed that sensitization with inactive subtilisin prevented eosinophil (Siglec-F⁺ MHC II⁺ cells) and neutrophil (Gr1^{high} MHC II⁺ cells) influx to the airways and to the lungs (Supplemental Fig. 2A). Furthermore, subtilisin protease activity was required for enhanced IL-4 production by lung CD4⁺ T cells; no IFN-γ was detected (Supplemental Fig. 2B). Accordingly, sensitization with active subtilisin led to an increased frequency (Supplemental Fig. 2C) and number (data not shown) of Gata-3-expressing CD4⁺ T cells in the lungs. No changes in Tbet-, Foxp3-, or Rorc-expressing T cells were observed comparing both groups (Supplemental Fig. 2C). In addition, protease activity was essential for the induction of total IgE Abs (Fig. 2C) and mucus production (Fig. 2D). Consistent with a previous report (15), enzymatic activity of papain was also essential for the development of allergic airway inflammation and IgE production (Fig. 2A–C). Of note, subtilisin activity was required only during sensitization for the development of allergic inflammation, as sensitization with active subtilisin and further challenge with the inactivated form did not prevent the establishment of allergic lung disease (data not shown). Also, heat inactivation of subtilisin worked equally well to inactivation by PMSF for both in vitro and in vivo experiments (data not shown). Together, our results indicate that Th2 responses to subtilisin were dependent on its protease activity.

Proteolytic activity can be directly sensed through a unique class of G protein-coupled molecules, the PARs (27). Because PAR-2 has been implicated in allergic inflammation (28), we aimed to determine the role of PAR-2 in subtilisin-induced airway inflammation. We found that PAR-2-deficient mice showed reduced eosinophil and neutrophil recruitment to the airways in response to subtilisin sensitization as compared with WT mice (Fig. 2E). IgE production was also reduced in subtilisin-sensitized PAR-2-deficient mice (Fig. 2F). Furthermore, frequency and numbers of lung IL-5- and IL-13-producing T cells (CD3⁺CD4⁺) were decreased in PAR-2-deficient mice (Supplemental Fig. 2D and data not shown, respectively). These data suggest that subtilisin initiation of allergic inflammation in the lung depends upon PAR-2.

Allergic sensitization to subtilisin is dependent on MyD88 adaptor molecule, but not TLR4

Innate signals have been increasingly recognized as fundamental for the initiation of allergic sensitization. MyD88 is the central signaling adaptor molecule for the TLRs and for the IL-1 family of cytokines (29) and for the initiation of some Th2-mediated responses (30). Some groups reported an important role of TLR4 in allergic inflammation induced by airborne allergens in house dust mite (31) or to the development of hypersensitivity contact in humans caused by nickel (32). Therefore, we wished to determine the role of MyD88 and TLR4 in Th2 responses induced by subtilisin. Airway eosinophilia was significantly reduced in subtilisin-sensitized MyD88-deficient mice, whereas no change was verified in TLR4-deficient mice (Supplemental Fig. 3A, 3B, 3D, *top*). Total serum IgE and frequency of IL-5-producing lung T cells from MyD88-deficient mice were similarly decreased, whereas no significant changes were observed in TLR4-deficient mice (Supplemental Fig. 3C, 3D, *bottom*). The inflammatory




FIGURE 1. Airway allergic inflammation induced by subtilisin. **(A)** Experimental protocol for the development of allergic airway inflammation. C57BL/6 mice were s.c. sensitized with subtilisin or papain with or without alum on days 0 and 7 and i.n. challenged with the respective enzyme on days 14 and 21. Control groups received saline, and samples were harvested on day 22, 24 h after the last enzyme challenge. **(B)** Total serum IgE and **(C)** subtilisin-specific IgG1. BAL **(D)** total and **(E)** differential cell counts. **(F)** Representative lung sections (stained with PAS and hematoxylin, original magnification $\times 200$) showing mucus production and peribronchovascular cellular infiltrates. **(G)** Remaining specific enzymatic activities of subtilisin (*left*) and papain (*right*) after incubation with different concentrations of alum. Error bars show *** $p \leq 0.0001$, ** $p \leq 0.001$, * $p \leq 0.01$ for significant differences to control group or *** $p < 0.0001$, ** $p < 0.001$, * $p < 0.05$ to protease without alum group. Data are mean $\pm$ SEM and are representative of three independent experiments ($n = 5$) (B–F) or are representative of, at least, five experiments (G).

cytokines IL-4, IL-6, and TNF- α as well as IL-10 were increased in the airways of both sensitized WT and TLR4-deficient mice, but not in MyD88 (Supplemental Fig. 3E). Thus, signaling through MyD88 adaptor molecule is essential for subtilisin-induced allergic lung inflammation. Because allergic responses to subtilisin were intact in TLR4-deficient mice, we also exclude a possible endotoxin contamination in subtilisin samples. Our data suggest there is another receptor that is required for the allergic response to subtilisin that signals through MyD88.

Subtilisin increases lung ILC2 frequency dependent on PAR-2

ILC2 are innate producers of type 2 cytokines and have been increasingly recognized as inducers of type 2 immunity (33). Because ILC2s are constitutively present in mouse lung tissue (34),

we examined ILC2 activation by administration of subtilisin into the airways. Notably, acute i.n. administration of subtilisin for consecutive 3 d (Fig. 3A) increased the frequency of IL-5–producing lung ILC2s (characterized by negative expression of the lineage markers CD3, CD19, CD11b, CD11c, Gr1, NK1.1, and positive expression of Thy-1.2⁺) (Fig. 3B). Next, we asked the role of PAR-2 on subtilisin-induced ILC2 activation in the lung. Interestingly, the increased frequency of lung ILC2 in response to acute airway sensitization to subtilisin was dependent on PAR-2 (Fig. 3B).

Because lung ILC2s were induced by i.n. exposure to subtilisin, we further decided to explore airway sensitization to this protease in the development of allergic inflammation. For this, we adapted for subtilisin a previously described protocol for papain (8), which consisted of two i.n. administrations with active subtilisin on days





FIGURE 2. Subtilisin serine protease activity and signaling through PAR-2 are both essential for the development of Th2 responses. C57BL/6 mice were s.c. sensitized with active or inactivated form of the enzyme, 10 μ M PMSF for subtilisin or 50 nM E-64 for papain, on days 0 and 7 and i.n. challenged with the active enzyme on days 14 and 21. Samples were harvested 24 h after the last i.n. administration, on day 22. BAL (A) total and (B) differential cell counts. (C) Total serum IgE. (D) Representative lung sections (stained with PAS and hematoxylin, original magnification $\times 200$). C57BL/6 WT or PAR-2^{-/-} mice were sensitized with s.c. subtilisin on days 0 and 7 and i.n. challenged on days 14 and 21. (E, left) Total number of cells from BAL recovered on day 22. (E, right) BAL neutrophil and eosinophil numbers from WT or PAR-2^{-/-} mice by morphological analysis. (F) Total serum IgE. Error bars show $***p < 0.0001$, $**p < 0.001$, $*p < 0.05$ for significant differences to sensitization with active protease (A–C) or to WT group (E and F). Data are mean $\pm$ SEM and are representative of three independent experiments ($n = 5$).

0 and 7 (Fig. 3C). BAL cell counts on day 8 showed that subtilisin treatment induced eosinophilia that depended on PAR-2 expression (Fig. 3D). Finally, because both epithelial cells and hematopoietic cells express PAR-2 (27, 35, 36), we generated mixed BM chimeras that would allow us to examine independently the contribution of different cell types expressing PAR-2. For this, irradiated PAR-2^{-/-} mice were reconstituted with WT BM (referred as WT BM to PAR-2^{-/-}), and vice versa (PAR-2^{-/-} BM to WT). Neither of the mixed BM chimeras developed lung eosinophilia in response to subtilisin, suggesting that PAR-2 expression is important in both hematopoietic and nonhematopoietic compartments for protease-induced development of allergic response to subtilisin (Fig. 3D).

Subtilisin stimulates airway epithelial cells to express pro-Th2 cytokines

Epithelial cell-derived factors have been implicated in allergic sensitization (37), and it is known that some of these molecules induce ILC2 activation (38). Hence, we investigated whether subtilisin activates epithelial cells and induces expression of proallergic cytokines. For this, we analyzed early gene expression of IL-1 α , TSLP, and IL-33 in a human bronchial epithelial cell line, H292. Subtilisin treatment induced these cytokines in a dose-dependent manner 3 h after stimulation, except for IL-33, whose expression peaked at 6 h (Fig. 4). Papain also induced expression of the same cytokines in H292 cells (Fig. 4); however, the intensity and kinetics were different from those seen with subtilisin

FIGURE 3. Role of PAR-2 in the induction of lung ILC2 and eosinophilia promoted by airway exposure to subtilisin. **(A)** To analyze lung ILC2, C57BL/6 WT or PAR-2^{-/-} mice received i.n. subtilisin for consecutive 3 d and lung cells were analyzed on day 4. **(B)** FACS plots show lung ILC2, as defined by CD45⁺Lin⁻Thy-1.2⁺, after ex vivo stimulation with PMA and ionomycin to induce cytokine production. **(C)** Experimental protocol used to promote allergic inflammation by airway sensitization to subtilisin. WT, total PAR-2^{-/-}, and the mixed chimera (WT BM to PAR-2^{-/-} and PAR-2^{-/-} BM to WT) mice were i.n. sensitized with 1 μ g subtilisin on days 0 and 7, and samples were harvested on day 8. **(D)** Number of BAL eosinophils from subtilisin-administered mice. Error bars show $*p \leq 0.01$ for significant differences to WT group. Data are mean $\pm$ SEM and are representative of two independent experiments ($n = 5$ –9 mice per group).



treatment, suggesting that these proteases might activate the epithelium through distinct pathways (Fig. 4). Interestingly, subtilisin or papain also enhanced the expression of amphiregulin, an epidermal growth factor family member that promotes proliferation and tissue repair and was previously recognized as a Th2 cytokine (39). Similar results were obtained using a murine lung epithelial cell line, LA-4 (data not shown). We did not find that either subtilisin or papain induced expression of IL-25 (IL-17E), a cytokine previously shown to induce Th2 responses (40) (data not shown).

DCs have been reported to play a pivotal role in the initiation of type 2 inflammation (41–43). To see whether the subtilisin pro-

moted DC activation, we generated human DCs, as described before (23). Our results show that active subtilisin was not able to induce expression of HLA-DR, CD80, CD83, or CD86 on immature DCs when compared with the positive control stimulated with LPS (Supplemental Fig. 4A). Similar data were obtained by using murine BM-derived DCs (data not shown). Furthermore, subtilisin-pulsed human DCs could not polarize CD3⁺ T cells to a Th2 phenotype (Supplemental Fig. 4B). Thus, we hypothesize DCs might not be the main cell type that senses subtilisin and triggers type 2 immunity, at least, not in a direct way. Because basophils were implicated in the initiation of type 2 responses to




FIGURE 4. Subtilisin stimulates airway epithelial cells to express pro-Th2 cytokines and amphiregulin. Expression of mRNA from IL-1 α (top left), TSLP (top right), IL-33 (bottom left), and amphiregulin (bottom right) in human bronchial epithelial cell line (H292) stimulated with active subtilisin or papain for 3 or 6 h at the indicated concentrations. FACS plots are representative of two independent experiments ($n = 5$ per group). Data are mean $\pm$ SEM and are representative of three independent experiments, each of them with triplicate samples.




FIGURE 5. Subtilisin-induced Th2 responses are dependent upon MyD88 and IL-33R ST2. C57BL/6 WT, MyD88^{-/-}, or Il1r1^{-/-} (ST2^{-/-}) mice were sensitized with i.n. subtilisin on days 0 and 7. Control groups received saline, and samples were harvested on day 8. **(A)** BAL granulocytes (eosinophils are shown on the left, and neutrophils on the right). **(B)** FACS plots show frequency of MHCII⁺CD3⁻CD19⁻ cells from BAL (top) or lung (bottom) of subtilisin-sensitized groups. **(C)** FACS plots show IL-5 and IL-13 production by lung conventional T cells (CD45⁺CD3⁺CD4⁺) after stimulation with PMA and ionomycin. Error bars show ** $p \leq 0.001$, * $p \leq 0.01$ for significant differences to control group or ** $p < 0.001$, * $p < 0.01$ to subtilisin-sensitized C57BL/6 WT. Data are mean $\pm$ SEM and are representative of two independent experiments ($n = 5$).

papain (14), we also determined the effect of subtilisin stimulation on BM-derived basophils, generated as previously described (44). Using the *4get* reporter system, we did not find significant IL-4 production by murine basophils stimulated with active subtilisin when compared with the positive control stimulated with papain (data not shown). Thus, our data suggest that subtilisin allergenicity works through the induction of epithelial cell-derived pro-Th2 cytokines.

Allergic inflammation to i.n. subtilisin requires the IL-33R, ST2, and MyD88

Given that our previous results indicated an important role for MyD88 during s.c. sensitization with subtilisin, we questioned whether this pathway was important during i.n. subtilisin exposure. MyD88-deficient mice exhibited impaired recruitment of inflammatory cells in BAL and a reduced frequency of IL-5- and IL-13-producing lung T cells (Fig. 5; number of cells, data not shown). These data indicate that MyD88 signaling is also required for the development of allergic airway responses to i.n. sensitization to subtilisin.

The epithelial-derived cytokine IL-33 is a potent inducer of ILC2 (45) and implicated in the development of type 2 immunity (46). Furthermore, the IL-33R, ST2 (Ilr1), is known to signal through MyD88 (30). Considering that our data indicated the importance of MyD88 for subtilisin allergenicity, we investigated the role of IL-33R signaling in the initiation of allergic inflammation to subtilisin. Mice lacking ST2 (Ilr1^{-/-}) had impaired eosinophil recruitment (Fig. 5A, left), whereas neutrophil recruitment was increased (Fig. 5A, right). Similar results were found by FACS analysis, as the frequency of eosinophils (Siglec-F⁺ MHCII⁺ cells) was substantially reduced, whereas neutrophil (Gr1⁺ MHCII⁺ cells) frequency was increased in the airways (Fig. 5B, top) and lungs (Fig. 5B, bottom) of ST2-deficient mice. Moreover, ST2-deficient mice showed reduced IL-5 and IL-13 production by lung conventional T cells (CD3⁺CD4⁺) (Fig. 5C). Our results suggest that

subtilisin induces a Th2 response through activation of IL-33/ST2 receptor that, in turn, signals through MyD88 (47).

Subtilisin can act as adjuvant and sensitize the airway to a bystander Ag

Because subtilisin activated lung innate allergic responses, we tested whether this serine protease might behave as a Th2 adjuvant to a bystander Ag. We chose to use OVA as the Ag, because its i.n. administration does not result in allergic inflammation (48). WT mice i.n. sensitized with subtilisin and OVA on days 0 and 7 and i.n. challenged with OVA alone on days 14 and 21 (Fig. 6A) showed an intense cellular influx to the airways mainly composed by eosinophils on day 22 (Fig. 6B, 6C). Our results also showed increased total IgE, OVA-specific IgE and IgG1 Abs (Fig. 6D), and mucus formation (Fig. 6E) in mice i.n. sensitized with both OVA and active subtilisin. The i.n. administration of OVA and heat-inactivated subtilisin did not induce airway allergic inflammation, production of Th2-related Abs, or mucus secretion triggered by OVA challenge (Fig. 6B–E), which indicates the requirement of subtilisin protease activity for OVA sensitization. Our data suggest that subtilisin promotes allergic inflammation to unrelated proteins.

Discussion

Subtilisin was identified as a potent allergen soon after its usage in the detergent industries (49, 50). Two decades ago, experimental models evaluated the allergenic potential of Carlsberg subtilisin (51–54); however, the mechanism was not elucidated. In this work, we developed a murine model of subtilisin-induced allergic airway disease and demonstrated that this enzyme is a potent inducer of type 2 immunity, including Th2 and ILC2 responses, and IgE production in mice. Our data show that the ability of subtilisin to induce Th2 response is dependent on its serine protease activity and on the expression of PAR-2, IL-33R ST2, and MyD88. These data support the hypothesis that detection of enzymatic activities




FIGURE 6. Subtilisin has adjuvant activity to a bystander Ag through airway sensitization. **(A)** C57BL/6 mice were i.n. administered with OVA plus active or heat-inactivated subtilisin and challenged with OVA. **(B)** Total (*left*) and **(C)** differential (*right*) cell counts in BAL. **(D)** Serum concentrations of total IgE (*left*), OVA-specific IgE (*middle*), and OVA-specific IgG1 (*right*). **(E)** Representative lung sections (stained with PAS and hematoxylin, original magnification $\times 200$). Error bars show *** $p \leq 0.0001$, ** $p \leq 0.001$ for significant differences to control groups or *** $p < 0.0001$, ** $p < 0.001$, * $p < 0.01$ to group sensitized with active subtilisin. Data are mean $\pm$ SEM and are representative of three independent experiments ($n = 5$).

in allergens can promote Th2 and IgE responses (55, 56) and offer a more integrated view of the innate mechanisms responsible for the development of type 2 inflammation to a serine protease.

The present study confirms, in a murine model of allergic asthma, the sensitization potential of subtilisin and extends its allergenic action to other classical features of OA rather than specific IgE and IgG1 Ab production, such as airway and lung eosinophilia, mucus production, type 2 cytokine production by lung Th2 cells, airway hyperreactivity, and late-phase response. Notably, low concentrations of subtilisin could promote these hallmarks of allergic asthma in the absence of alum, a strong type 2 adjuvant. In fact, our work indicates that usage of alum does not represent a good immunization strategy to maximize the response to proteases because alum impairs both serine and cysteine enzymatic activities.

We showed subtilisin is, by itself, a potent inducer of type 2 immunity and suggested that its serine protease activity is responsible for the development of Th2 responses. Accumulating evidence suggests that intrinsic proteolytic activity not only facilitates allergen sensitization, but also diminishes epithelial barrier integrity, enhances cytokine and chemokine expression as well as affects lung chronic inflammation and directs airway remodeling, followed by interactions with bronchial epithelium (57, 58). Some mechanisms involved in the induction of Th2 response described to serine proteases have in common the activation of PAR-2 (27, 59, 60). Indeed, we found a critical role for this direct protease sensor in the development of allergic responses to subtilisin. Recently, Page et al. (59) showed PAR-2 contribution to allergic inflammation to German cockroach proteases in feces (frass) only when the allergen was administered through the airway mucosa, but not into the peritoneal cavity. In our work, PAR-2 was found to be required when subtilisin was administered either s.c. or i.n.

Because airway epithelial cells responded fast and directly to subtilisin in vitro by expressing proallergic cytokines, we predict that the Th2-inducing effects of subtilisin might be largely dependent on the activation of PAR-2 on epithelial cells. It was shown that signaling through this receptor triggered by the recognition of enzymatic activity leads to TSLP production in epithelial cells from the respiratory tract (61). This production can, in turn, enhance OX-40L expression in DCs and promotes effector functions of basophils and other granulocytes (62). But besides its important role in airway sensitization to subtilisin, PAR-2 was also important in s.c. sensitization, suggesting other cell types such as keratinocytes might be involved in allergic response to this enzyme. Accordingly, mite proteases were shown to promote allergic inflammation through PAR-2 activation of human keratinocytes (60), and a recent work also evidenced the role of this receptor in a model of atopic dermatitis (63). Interestingly, however, is the fact that PAR-2 expression was important in hematopoietic cells as well as in nonhematopoietic compartment for the allergic process promoted by subtilisin. This indicates epithelial cells might not be the only cell type responsible for subtilisin allergic response.

A recent report showed a direct effect of a cockroach serine protease, Per a 10, on human DC activation and T cell polarization toward a Th2 phenotype and suggested enzymatic activity as responsible for driving the allergic response to Per a 10 (64). For the cysteine protease papain, Sokol et al. (15) proposed that basophils are a possible cell type responsible for the initiation of allergic response through TSLP production, and two recent studies characterized a particular DC subset required for the development of Th2 immunity in response to papain (42, 43). In our work, the serine protease subtilisin was unable to directly activate DCs or basophils and promote further Th2 differentiation. However, subtilisin activated human epithelial cells to enhance expression of proallergic cytokines, which could, in turn, act on DCs and promote type 2 immunity, as previously shown for IL-33 and TSLP (65, 66).

Importantly, we found that subtilisin is a potent inducer of ILC2 in the lung, and this is also dependent on PAR-2 expression. This newly identified cell subset represents a large proportion of IL-5- and IL-13-producing cells in the lungs (38). Also, it has been shown that mice deficient in ILC2 cells showed decreased lung inflammation after i.n. papain (67). A detailed study investigating the contribution of ILC2 and PAR-2 will be necessary for better understanding the interaction between innate and adaptive immunity during type 2 responses.

A few studies have highlighted the critical role of IL-33/ST2 in type 2 inflammation and allergic disease states (46). IL-33 plays a role in innate type 2 responses by inducing the expansion of ILC2, which produces IL-5 and IL-13 and contributes to respiratory or gastrointestinal inflammation and antihelminth responses (68). Moreover, a role for MyD88 and ST2 in driving the Th2 response to *Trichinella spiralis* has recently been demonstrated (69). We found in this work that ST2 is required for the induction of subtilisin-induced Th2 responses. Likewise, MyD88 expression is essential for optimal Th2 responses to subtilisin. Because prevention of allergic response to subtilisin is more pronounced in MyD88-deficient mice than in ST2 mice, we hypothesize that other cytokine, which also signals through the same adaptor rather than IL-33, might play an important role in our model.

It was previously shown that PAR-2 and TLR4 receptors, through MyD88, synergistically cooperate to inflammatory responses (70); however, we could not find a role for TLR4 signaling in our model. Although PAR-2 was essential for the induction of Th2 responses in this work, a recent study demonstrated that induction of pro-inflammatory cytokines by house dust mite exposure is independent of PAR-2 (71), indicating that alternative pathways, besides PAR-2, could be involved in protease-mediated inflammation. For example, papain has been shown to induce IL-4 production in basophils because it requires calcium flux, activation of PI3K, and NF-AT through a yet unknown receptor (44). The challenge for future studies, therefore, is to determine the direct sensor in each case and their respective biological contribution to the development of type 2 inflammation.

Based on our in vitro data with epithelial cell line and work from Hammad and colleagues (72), we hypothesize that IL-1 α might also be important in allergic responses to subtilisin. IL-1 α and IL-33 cytokines, also known as alarmins, are sensors of tissue distress. Subtilisin also promoted enhanced expression of the tissue repair factor amphiregulin. As these molecules were induced in epithelial cells in vitro, some level of injury in vivo is anticipated; however, we could not detect alterations indicating rupture of lung structure, besides inflammation, when analyzing lung sections. Nevertheless, independently of the degree of tissue damage, our results indicate that PAR-2, ST-2, and MyD88 molecules are crucial to induce allergic responses.

The way workers in the detergent industry were sensitized to serine proteases remains to be elucidated. Consistent with data shown in this work, they could have been sensitized by either epicutaneous route or aerosol inhalation. In addition to directly sensitizing mice through the airways, subtilisin showed a strong Th2 adjuvant activity to a bystander innocuous OVA protein. This indicates that airway exposure to subtilisin can promote allergic response to the enzyme itself or to a neo airborne Ag, therefore increasing the risk to develop asthma to environmental proteins.

Taken together, our data indicate that allergenic effect of subtilisin enzyme activity depends on PAR-2, IL-33/ST2, and MyD88 signaling pathways. These observations have implications in allergy models induced by proteases. In conclusion, our study defines a new model of OA induced by the serine protease subtilisin and

provides another example of how protease sensing induces conserved type 2 immunity.

Acknowledgments

We thank members of the Russo and Medzhitov laboratories, especially Daniel Okin and Tanya Bondar, for helpful and crucial discussions and Cuiling Zhang for technical assistance in the generation of PAR-2 chimeras. We also thank Clélia Ferreira and Walter Terra from the Department of Biochemistry, University of Sao Paulo, for collaboration and expert advice on enzymology, Charles Annicelli and Sophie Cronin for animal care and technical help at Yale University, and Andrew McKenzie from University of Cambridge for making available the Il1rl1^{-/-} mice.

Disclosures

The authors have no financial conflicts of interest.

References

- Pawankar, R., G. W. Canonica, S. T. Holgate, and R. F. Lockey. 2011. *WAO White Book on Allergy 2011-2012: Executive Summary*. World Allergy Organization, Milwaukee, WI.
- Kim, H. Y., R. H. DeKruyff, and D. T. Umetsu. 2010. The many paths to asthma: phenotype shaped by innate and adaptive immunity. *Nat. Immunol.* 11: 577–584.
- Maestrelli, P., P. Boschetto, L. M. Fabbri, and C. E. Mapp. 2009. Mechanisms of occupational asthma. *J. Allergy Clin. Immunol.* 123: 531–542, quiz 543–544.
- Baur, X. 2005. Enzymes as occupational and environmental respiratory sensitizers. *Int. Arch. Occup. Environ. Health* 78: 279–286.
- Dykewicz, M. S. 2009. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. *J. Allergy Clin. Immunol.* 123: 519–528, quiz 529–530.
- Schweigert, M. K., D. P. Mackenzie, and K. Sarlo. 2000. Occupational asthma and allergy associated with the use of enzymes in the detergent industry—a review of the epidemiology, toxicology and methods of prevention. *Clin. Exp. Allergy* 30: 1511–1518.
- Lemière, C., A. Cartier, J. Dolovich, and J. L. Malo. 1996. Isolated late asthmatic reaction after exposure to a high-molecular-weight occupational agent, subtilisin. *Chest* 110: 823–824.
- Kamijo, S., H. Takeda, T. Tokura, M. Suzuki, K. Inui, M. Hara, H. Matsuda, A. Matsuda, K. Oboki, T. Ohno, et al. 2013. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. *J. Immunol.* 190: 4489–4499.
- Shafique, R. H., P. B. Klimov, M. Inam, F. R. Chaudhary, and B. M. O'Connor. 2014. Group 1 allergen genes in two species of house dust mites, *Dermatophagoides farinae* and *D. pteronyssinus* (Acari: Pyroglyphidae): direct sequencing, characterization and polymorphism. *PLoS One* 9: e114636.
- Shen, H.-D., M. F. Tam, R.-B. Tang, and H. Chou. 2007. *Aspergillus* and *Penicillium* allergens: focus on proteases. *Curr. Allergy Asthma Rep.* 7: 351–356.
- Sudha, V. T., N. Arora, S. N. Gaur, S. Pasha, and B. P. Singh. 2008. Identification of a serine protease as a major allergen (Per a 10) of *Periplaneta americana*. *Allergy* 63: 768–776.
- Grobe, K., M. Pöppelmann, W.-M. Becker, and A. Petersen. 2002. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. *Eur. J. Biochem.* 269: 2083–2092.
- Suck, R., A. Petersen, S. Hagen, O. Cromwell, W. M. Becker, and H. Fiebig. 2000. Complementary DNA cloning and expression of a newly recognized high molecular mass allergen phl p 13 from timothy grass pollen (*Phleum pratense*). *Clin. Exp. Allergy* 30: 324–332.
- Ibrahim, A. R. N., S. Kawamoto, T. Aki, Y. Shimada, S. Rikimaru, N. Onishi, E. E. Babiker, I. Oiso, K. Hashimoto, T. Hayashi, and K. Ono. 2010. Molecular cloning and immunochemical characterization of a novel major Japanese cedar pollen allergen belonging to the aspartic protease family. *Int. Arch. Allergy Immunol.* 152: 207–218.
- Sokol, C. L., G. M. Barton, A. G. Farr, and R. Medzhitov. 2008. A mechanism for the initiation of allergen-induced T helper type 2 responses. *Nat. Immunol.* 9: 310–318.
- Cunningham, P. T., C. E. Elliot, J. C. Lenzo, A. G. Jarnicki, A. N. Larcombe, G. R. Zosky, P. G. Holt, and W. R. Thomas. 2012. Sensitizing and Th2 adjuvant activity of cysteine protease allergens. *Int. Arch. Allergy Immunol.* 158: 347–358.
- Chapman, M. D., S. Wünschmann, and A. Pomés. 2007. Proteases as Th2 adjuvants. *Curr. Allergy Asthma Rep.* 7: 363–367.
- Schmidt, D., J. Verdager, N. Averill, and P. Santamaria. 1997. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. *J. Exp. Med.* 186: 1059–1075.
- Keller, A. C., D. Mucida, E. Gomes, E. Faquim-Mauro, A. M. C. Faria, D. Rodriguez, and M. Russo. 2006. Hierarchical suppression of asthma-like responses by mucosal tolerance. *J. Allergy Clin. Immunol.* 117: 283–290.
- Hollingsworth, J. W., II, D. N. Cook, D. M. Brass, J. K. L. Walker, D. L. Morgan, W. M. Foster, and D. A. Schwartz. 2004. The role of Toll-like receptor 4 in environmental airway injury in mice. *Am. J. Respir. Crit. Care Med.* 170: 126–132.

21. Whitehead, G. S., J. K. L. Walker, K. G. Berman, W. M. Foster, and D. A. Schwartz. 2003. Allergen-induced airway disease is mouse strain dependent. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 285: L32–L42.
22. Russo, M., M. A. Nahori, J. Lefort, E. Gomes, A. de Castro Keller, D. Rodriguez, O. G. Ribeiro, S. Adriouch, V. Gallois, A. M. de Faria, and B. B. Vargafig. 2001. Suppression of asthma-like responses in different mouse strains by oral tolerance. *Am. J. Respir. Cell Mol. Biol.* 24: 518–526.
23. Ramos, R. N., L. S. Chin, A. P. Dos Santos, P. C. Bergami-Santos, F. Laginha, and J. A. Barbuto. 2012. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. *J. Leukoc. Biol.* 92: 673–682.
24. Bortolatto, J., E. Borducchi, D. Rodriguez, A. C. Keller, E. Faquim-Mauro, K. R. Bortoluci, D. Mucida, E. Gomes, A. Christ, S. Schnyder-Candrian, et al. 2008. Toll-like receptor 4 agonists adsorbed to aluminum hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. *Clin. Exp. Allergy* 38: 1668–1679.
25. Soto-Mera, M. T., M. R. López-Rico, J. F. Filgueira, E. Villamil, and R. Cidrás. 2000. Occupational allergy to papain. *Allergy* 55: 983–984.
26. Herxheimer, H. 1952. The late bronchial reaction in induced asthma. *Int. Arch. Allergy Appl. Immunol.* 3: 323–328.
27. Shpacovitch, V., M. Feld, N. W. Bunnett, and M. Steinhoff. 2007. Protease-activated receptors: novel PARtners in innate immunity. *Trends Immunol.* 28: 541–550.
28. Schmidlin, F., S. Amadesi, K. Dabbagh, D. E. Lewis, P. Knott, N. W. Bunnett, P. R. Gater, P. Geppetti, C. Bertrand, and M. E. Stevens. 2002. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. *J. Immunol.* 169: 5315–5321.
29. Dinarello, C. A. 2009. Immunological and inflammatory functions of the interleukin-1 family. *Annu. Rev. Immunol.* 27: 519–550.
30. Kroeger, K. M., B. M. Sullivan, and R. M. Locksley. 2009. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. *J. Leukoc. Biol.* 86: 769–778.
31. Hammad, H., M. Chieppa, F. Perros, M. A. Willart, R. N. Germain, and B. N. Lambrecht. 2009. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nat. Med.* 15: 410–416.
32. Schmidt, M., B. Raghavan, V. Müller, T. Vogl, G. Fejer, S. Tchaptchet, S. Keck, C. Kalis, P. J. Nielsen, C. Galanos, et al. 2010. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. *Nat. Immunol.* 11: 814–819.
33. Walker, J. A., and A. N. McKenzie. 2013. Development and function of group 2 innate lymphoid cells. *Curr. Opin. Immunol.* 25: 148–155.
34. Monticelli, L. A., G. F. Sonnenberg, M. C. Abt, T. Alenghat, C. G. Ziegler, T. A. Doering, J. M. Angelosanto, B. J. Laidlaw, C. Y. Yang, T. Sathaliyawala, et al. 2011. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. *Nat. Immunol.* 12: 1045–1054.
35. Cocks, T. M., and J. D. Moffatt. 2001. Protease-activated receptor-2 (PAR2) in the airways. *Pulm. Pharmacol. Ther.* 14: 183–191.
36. Lewkowich, I. P., S. B. Day, J. R. Ledford, P. Zhou, K. Dienger, M. Wills-Karp, and K. Page. 2011. Protease-activated receptor 2 activation of myeloid dendritic cells regulates allergic airway inflammation. *Respir. Res.* 12: 122.
37. Saenz, S. A., B. C. Taylor, and D. Artis. 2008. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. *Immunol. Rev.* 226: 172–190.
38. Klein Wolterink, R. G. J., A. Kleijman, M. van Nimwegen, I. Bergen, M. de Bruijn, Y. Levani, and R. W. Hendriks. 2012. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. *Eur. J. Immunol.* 42: 1106–1116.
39. Zaiss, D. M., L. Yang, P. R. Shah, J. J. Kobia, J. F. Urban, and T. R. Mosmann. 2006. Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. *Science* 314: 1746.
40. Tamachi, T., Y. Maezawa, K. Ikeda, S. Kagami, M. Hatano, Y. Seto, A. Suto, K. Suzuki, N. Watanabe, Y. Saito, et al. 2006. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. *J. Allergy Clin. Immunol.* 118: 606–614.
41. Hammad, H., M. Plantinga, K. Deswarte, P. Pouliot, M. A. Willart, M. Kool, F. Muskens, and B. N. Lambrecht. 2010. Inflammatory dendritic cells—not basophils—are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. *J. Exp. Med.* 207: 2097–2111.
42. Kumamoto, Y., M. Linehan, J. S. Weinstein, B. J. Laidlaw, J. E. Craft, and A. Iwasaki. 2013. CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity. *Immunity* 39: 733–743.
43. Gao, Y., S. A. Nish, R. Jiang, L. Hou, P. Licona-Limón, J. S. Weinstein, H. Zhao, and R. Medzhitov. 2013. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. *Immunity* 39: 722–732.
44. Rosenstein, R. K., J. S. Bezbradica, S. Yu, and R. Medzhitov. 2014. Signaling pathways activated by a protease allergen in basophils. *Proc. Natl. Acad. Sci. USA* 111: E4963–E4971.
45. Spooner, C. J., J. Lesch, D. Yan, A. A. Khan, A. Abbas, V. Ramirez-Carrozzi, M. Zhou, R. Soriano, J. Eastham-Anderson, L. Diehl, et al. 2013. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. *Nat. Immunol.* 14: 1229–1236.
46. Townsend, M. J., P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. J. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. *J. Exp. Med.* 191: 1069–1076.
47. Kakkar, R., and R. T. Lee. 2008. The IL-33/ST2 pathway: therapeutic target and novel biomarker. *Nat. Rev. Drug Discov.* 7: 827–840.
48. Wikstrom, M. E., E. Batanero, M. Smith, J. A. Thomas, C. von Garnier, P. G. Holt, and P. A. Stumbles. 2006. Influence of mucosal adjuvants on antigen passage and CD4⁺ T cell activation during the primary response to airborne allergen. *J. Immunol.* 177: 913–924.
49. Pepys, J., J. L. Longbottom, F. E. Hargreave, and J. Faux. 1969. Allergic reactions of the lungs to enzymes of *Bacillus subtilis*. *Lancet* 1: 1181–1184.
50. Flindt, M. L. 1969. Pulmonary disease due to inhalation of derivatives of *Bacillus subtilis* containing proteolytic enzyme. *Lancet* 1: 1177–1181.
51. Blaikie, L., and D. A. Basketter. 1999. Experience with a mouse intranasal test for the predictive identification of respiratory sensitization potential of proteins. *Food Chem. Toxicol.* 37: 889–896.
52. Robinson, M. K., L. S. Babcock, P. A. Horn, and T. T. Kawabata. 1996. Specific antibody responses to subtilisin Carlsberg (Alcalase) in mice: development of an intranasal exposure model. *Fundam. Appl. Toxicol.* 34: 15–24.
53. Sarlo, K., H. L. Ritz, E. R. Fletcher, K. R. Schrotel, and E. D. Clark. 1997. Proteolytic detergent enzymes enhance the allergic antibody responses of guinea pigs to nonproteolytic detergent enzymes in a mixture: implications for occupational exposure. *J. Allergy Clin. Immunol.* 100: 480–487.
54. Kawabata, T. T., L. S. Babcock, and P. A. Horn. 1996. Specific IgE and IgG1 responses to subtilisin Carlsberg (Alcalase) in mice: development of an intratracheal exposure model. *Fundam. Appl. Toxicol.* 29: 238–243.
55. Shakib, F., A. M. Ghaemmaghami, and H. F. Sewell. 2008. The molecular basis of allergenicity. *Trends Immunol.* 29: 633–642.
56. Wills-Karp, M., A. Nathan, K. Page, and C. L. Karp. 2010. New insights into innate immune mechanisms underlying allergenicity. *Mucosal Immunol.* 3: 104–110.
57. Jacquet, A. 2011. Interactions of airway epithelium with protease allergens in the allergic response. *Clin. Exp. Allergy* 41: 305–311.
58. Takai, T., and S. Ikeda. 2011. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. *Allergol. Int.* 60: 25–35.
59. Page, K., J. R. Ledford, P. Zhou, K. Dienger, and M. Wills-Karp. 2010. Mucosal sensitization to German cockroach involves protease-activated receptor-2. *Respir. Res.* 11: 62.
60. Kato, T., T. Takai, T. Fujimura, H. Matsuoka, T. Ogawa, K. Murayama, A. Ishii, S. Ikeda, K. Okumura, and H. Ogawa. 2009. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. *Allergy* 64: 1366–1374.
61. Kouzaki, H., S. M. O'Grady, C. B. Lawrence, and H. Kita. 2009. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. *J. Immunol.* 183: 1427–1434.
62. Miazgowiec, M. M., M. B. Headley, R. P. Larson, and S. F. Ziegler. 2009. Thymic stromal lymphopoietin and the pathophysiology of atopic disease. *Expert Rev. Clin. Immunol.* 5: 547–556.
63. Wilson, S. R., L. Thé, L. M. Batia, K. Beattie, G. E. Katibah, S. P. McClain, M. Pellegrino, D. M. Estandian, and D. M. Bautista. 2013. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. *Cell* 155: 285–295.
64. Goel, C., D. Govindaraj, B. P. Singh, A. Farooque, N. Kalra, and N. Arora. 2012. Serine protease Per a 10 from *Periplaneta americana* bias dendritic cells towards type 2 by upregulating CD86 and low IL-12 secretions. *Clin. Exp. Allergy* 42: 412–422.
65. Su, Z., J. Lin, F. Lu, X. Zhang, L. Zhang, N. B. Gandhi, C. S. de Paiva, S. C. Pflugfelder, and D. Q. Li. 2013. Potential autocrine regulation of interleukin-33/ST2 signaling of dendritic cells in allergic inflammation. *Mucosal Immunol.* 6: 921–930.
66. Leyva-Castillo, J. M., P. Hener, P. Michea, H. Karasuyama, S. Chan, V. Soumelis, and M. Li. 2013. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. *Nat. Commun.* 4: 2847.
67. Halim, T. Y., A. MacLaren, M. T. Romanish, M. J. Gold, K. M. McNagny, and F. Takei. 2012. Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. *Immunity* 37: 463–474.
68. Oliphant, C. J., J. L. Barlow, and A. N. J. McKenzie. 2011. Insights into the initiation of type 2 immune responses. *Immunology* 134: 378–385.
69. Scalfone, L. K., H. J. Nel, L. F. Gagliardo, J. L. Cameron, S. Al-Shokri, C. A. Leifer, P. G. Fallon, and J. A. Appleton. 2013. Participation of MyD88 and interleukin-33 as innate drivers of Th2 immunity to *Trichinella spiralis*. *Infect. Immun.* 81: 1354–1363.
70. Nhu, Q. M., K. Shirey, J. R. Teijaro, D. L. Farber, S. Netzel-Arnett, T. M. Antalis, A. Fasano, and S. N. Vogel. 2010. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. *Mucosal Immunol.* 3: 29–39.
71. Post, S., I. H. Heijink, A. H. Petersen, H. G. de Bruin, A. J. M. van Oosterhout, and M. C. Nawijn. 2014. Protease-activated receptor-2 activation contributes to house dust mite-induced IgE responses in mice. *PLoS One* 9: e91206.
72. Willart, M. A., K. Deswarte, P. Pouliot, H. Braun, R. Beyaert, B. N. Lambrecht, and H. Hammad. 2012. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. *J. Exp. Med.* 209: 1505–1517.